Effects of Continuous Use of Oral Drospirenone/Estradiol on Lipid Profile, Body Weight, and BP in Females from Early Menopause.

Abstract

Background: DRSP (drospirenone) is a progestin that has antiandrogenic and anti-mineralocorticoid activity. When used combined with estradiol (E2), drospirenone helps in relieving symptoms of menopause.

Aim: To assess the effects of continuous use of oral drospirenone/estradiol on lipid profile, body weight, and BP to minimize cardiovascular risk in females with early menopause.

Methods: The present study assessed 128 menopausal females with a mean amenorrhoeic period, mean BMI, and mean age of 2.46 ± 2.44 years, 25.06 ± 2.92 kg/m2, and 49.17 ± 4.60 years, respectively. Effects of combined oral drospirenone/estradiol in 1 mg dose were assessed on lipid levels, hormones, anthropometric data, heart rate, and BP variability in early menopausal females with untreated stage 1 hypertension. All subjects were assessed before and after 12 months of therapy.

Results: DRSP/E2 resulted in significant BP reduction during 6 and 12 months of therapy, with systolic and diastolic BP reduction in -4.50 to -8.50 and -4.0 to -5.0 mm Hg, respectively. No significant change in nocturnal 24-hour BP, significant day-time and night-time reduction at follow-up in HR, significant reduction in BMI, apolipoprotein B, and cholesterol were observed.

Conclusions: The present study concludes that continuous and long-term therapy using oral drospirenone/estradiol leads to a significant reduction in cardiovascular diseases and better BP control.